Pharmacology Biochemistry & Behavior, Vol. 23, 1985. © Ankho International Inc. Printed in the U.S.A.

VOLUME 23 1985

SUBJECT INDEX

Abstinence, 1059
  CNS binding
  morphine dependence
Abstinence syndrome, 457
  ethyl ketocyclazocine
  morphine
Acquisition
  chlordiazepoxide, 487
  discrimination, 487
  drug interaction, 1051
  food reward, 199
  monkeys, 1051
  naloxone, 199
  opioids, 199
  self-stimulation, 199
  THC, 1051
ACTH 4–9, 367
  auditory evoked potentials
Adenylate cyclase, 501
  cAMP
  lordosis response
  progesterone
α-Adrenergic agonist, 541
  antidepressants
  carbohydrate ingestion
  paraventricular nucleus
β-Adrenergic antagonist, 27
  memory spread
  propranolol
Adrenergic receptors, 495
  dopamine receptors
  exercise
  operant behavior
  running
Aggression
  benzodiazepine-receptor, 17
  diazepam, 17
  isolation, 17
  opiate receptors, 871
  social interaction, 871
Aging, 49
  lead
  passive avoidance
Agonist/antagonist, 637
  CGS 8216
  CGS 9896
  quantitative autoradiography
Alcohol, 959
  anticonvulsant
  kindling
  tolerance
Alcohol withdrawal, 71
  essential fatty acids
  ethanol
  prostaglandins
cAMP, 501
  adenylate cyclase
  lordosis response
  progesterone
Amphetamine
  aversion, 355
  caffeine, 303, 499
  cathinone, 355
  chronic drug treatment, 949
  corticotropin releasing factor, 303
  drug discrimination, 949
  fixed ratio schedule, 417
  haloperidol, 949
  heroin, 303, 499
  locomotor activity, 99, 303, 499
  naloxone, 499
  operant behavior, 355
  perseveration, 173
  phencyclidine, 99
  rate-dependency, 355
  stereotypy, 99
  stress, 173
  thermal stressors, 417
d-Amphetamine, 519
  fixed-interval self-stimulation
  lateral hypothalamus
  β-phenylethylamine
Analgesia
  animal model, 1045
  antinociception, 1045
  brain stimulation, electrical, 931
  cold water swim, 749
  desipramine, 749
  electric shock, 769
  morphine, 931
  morphine cross tolerance, 883
  motor suppression, 769
  naloxone, 883
  opioid peptides, 769
  pain, 749
  social conflict, 883
  Tyr-MIF-1, 1045
Animal model
  analgesia, 1045
  antinociception, 1045
  anxiolytic activity, 645
  compound IV, 645
  exploration, 461
  hallucinogens, 461
  locomotor activity, 461
  phenylpiperazines, 645
  Tyr-MIF-1, 1045
Anorexia
  body weight, 161, 551
  eating, 161
  fenfluramine, 551
  pergolide mesylate, 161
  tolerance, 551
Anticholinergic drugs, 1
  distal visual cues
  scopolamine
  spatial memory
Anticonvulsant, 959
  alcohol
  kindling
  tolerance
Antidepressants, 541
  α-adrenergic agonist
  carbohydrate injection
  paraventricular nucleus
Antiemetics, 259
  cancer chemotherapy
  conditioned taste aversion
Antinociception, 1045
  analgesia
  animal model
  Tyr-MIF-1
Antiobesity drugs, 811
  carbohydrate absorption
  lipid metabolism
  meal patterns
Anxiety
  busipirone, 687
  benzodiazepine binding sites, 737
  nonbenzodiazepine, 687
  PK 11195, 737
  stress, 737
Anxiolytic activity
  animal models, 645
  compound IV, 645
  phenylpiperazines, 645
  pyrazolopyridines, 675
  tracazolate, 675
Apomorphine
  climbing, 555
  clorgyline, 921
  drug interaction, 921
  inbred mice, 555
  locomotor activity, 555
  pargyline, 921
  [^{3}H]spiroperidol binding, 921
  stereotypy, 921
Apparatus
  behavioral pattern monitor (BPM), 461
  radial arm maze, 49
Atropine, 781
  forced lever
  mecamylamine
  methamphetamine
  motor control
  physostigmine
Attention, 1019
  lesions, hippocampal
  lesions, neocortical
  lesions, sham
  Org 2766
Auditory evoked potentials, 367
  ACTH 4–9
Autoradiography, 973
  benzodiazepines
  receptor sites
Aversion
  amphetamine, 355
  cathinone, 355
  drinking, 559
  eating, 559
  endorphins, 877
  human studies, 559
  memory, 37
  operant behavior, 355
  opioids, 877
  place preference, 37
  putative satiety glycoprotein, 559

rate-dependency, 355
reward, 877
satietin, 559
self-administration, 877
Aversive brain stimulation, 1069
chlordiazepoxide
IC injections
morphine
Avoidance
catecholamines, 107
chlordiazepoxide, 231
p-chloroamphetamine, 107
clozapine, 231
drug comparisons, 231
escape, 225, 231
haloperidol, 231
inhibition, 137
metabolism, 137
serotonin release, 107
soman, 225
trazodone, 137

Baboons
ketamine, 743
neurobehavioral response, 1003
phencyclidine, 743
reaction times, 743
seizures, 1003
sensory thresholds, 743
soman, sublethal exposure, 1003
Barbiturates
benzodiazepines, 285
convulsants, 285
GABAergic transmission, 285
monoamine neurotransmitters, 215
phenobarbital, 215
RO5-4864, 285
Basal ganglia, 207
bodily asymmetry
enkephalins
rotational behavior
Behavior, 857
endorphins
exercise
Behavioral audiometry, 401
clinical blood chemistry
toluene/alcohol interaction
Benzodiazepine binding sites, 737
anxiety
PK 11195
stress
Benzodiazepine receptor, 17
aggression
diazepam
isolation
Benzodiazepine receptor agonists, 671
binding studies
GABA benzodiazepine receptor complex
inverse benzodiazepine agonists
Benzodiazepines
autoradiography, 973
barbiturates, 285
binding sites, 681
caffeine, 237
CGS 8216, 33
chlordiazepoxide, 33
convulsants, 285
drug interactions, 33
fighting behavior, 237
GABAergic transmission, 285
heterogeneity, 681
receptor sites, 973
RO5-4864, 285
social interaction, 33
Binding sites, 681
benzodiazepines
heterogeneity
Binding studies, 671
benzodiazepine receptor agonists
GABA benzodiazepine receptor complex
inverse benzodiazepine agonists
Biodisposition, 607
drug discrimination
phencyclidine
smoking
Body asymmetry, 207
basal ganglia
enkephalins
rotational behavior
Body temperature
ethanol sensitivity, 309
heart rate, 325
morphine, 505
narcosis, 505
nicotine effects, 325
pentobarbital, 505
sex differences, mice, 309
startle response, 325
Y-maze, 325
Body weight
anorexia, 161, 551
caloric expenditure, 851
eating, 161
fenfluramine, 551
nicotine, 851
pergolide mesylate, 161
physical activity, 851
tolerance, 551
Bombesin, 243
dopamine receptor blockade
locomotor activity
mediation
Brain
amygdala, 333, 379
anterior caudate nucleus-putamen, 843
autoradiography, 973
basal ganglia, 207
brainstem, 1059
caudate-putamen, 207
central nervous system, 185
cerebellum, 153, 637, 973
cerebral cortex, 501, 973
cingular cortex, 697
contralateral striatum, 295
cortex, 153, 573
dentate gyrus, 637
dorsal periaqueductal gray, 1069
dorsomedial nucleus, 431
dorsomedial subiculum, 489
frontal cortex, 1059
globus pallidus, 207
hippocampus, 27, 195, 379, 489, 619, 637, 1019, 1059
hypophysis, 697
hypothalamus, 21, 141, 215, 253, 379, 697
lateral hypothalamus, 519, 777, 943
lateral ventricle, 411
locus coeruleus, 65, 93
medial basal hypothalamus, 397
median raphe nucleus, 943
medulla oblongata/pons, 153
mesencephalic central gray, 931
midbrain, 153
midbrain central gray, 797
neostriatum, 479
nucleus accumbens, 295, 411, 479, 843, 1029
nucleus basalis, 125
paraventricular nucleus, 431, 541
perifornical hypothalamus, 431
preoptic area, 501
pyriform cortex, 843
septum, 505
striatum, 215, 295, 1059
substantia nigra, 65, 295, 973
thalamus, 379
ventral tegmental area, 411, 931
ventromedial hypothalamus, 501, 917
ventromedial nucleus, 431
zona incerta, 973
Brain metabolism, 379
methylphenidate
stress
ulcer
Brain self-stimulation, 797
fixed ratio responding
locomotor activity
opioid antagonists
Brain stimulation, electrical, 931
analgesia
morphine
Brain stimulation reward, 777
haloperidol
pimozide
self-stimulation
trifluoperazine
Brain temperature, 953
DSIP
sleep-promoting substances
Brown adipose tissue, 509
fenfluramine
GDP-binding
Bulbectomy, 65
desipramine
5,7-dihydroxytryptamine
ECS
locus coeruleus
muricide
6-OHDA
substantia nigra
Buprenorphine, 1037
eating
monkeys
Busipirone, 687
anxiety
nonbenzodiazepine

Caffeine
amphetamine, 303, 499
benzodiazepines, 237
corticotropin releasing factor, 303
drug interaction, 633
fighting behavior, 237
heroin, 303, 499
locomotor activity, 85, 303, 499, 515
mimetic responses, 515
naloxone, 499
neophobia, 515
spatial learning, 85
taste aversion, 515

tolerance, 633
tunnel maze, 85
wheelrunning, 633
Caffeine-induced lethality, 275
inbred mice
pharmacogenetics
Calcium, 627
calmodulin antagonists
ethanol-induced sleep
Calcium channel inhibitors, 613
phencyclidine
stimulation
Calmodulin antagonists, 627
calcium
ethanol-induced sleep
Caloric expenditure, 851
body weight
nicotine
physical activity
Cancer chemotherapy, 259
antiemetics
conditioned taste aversion
Cannabidiol, 13
cannabinol
naloxone
quasi-morphine withdrawal syndrome
Δ-9-THC
Cannabinol, 13
cannabidiol
naloxone
quasi-morphine withdrawal syndrome
Δ-9-THC
Carbohydrate absorption, 811
antiobesity drugs
lipid metabolism
meal patterns
Carbohydrate ingestion, 541
α-adrenergic agonist
antidepressants
paraventricular nucleus
Carbohydrates, 721
eating
histidine
protein
Catalepsy, 911
haloperidol
molindone
neuroleptics
Cataleptic behavior, 789
dopamine receptors
stereotyped behavior
Catecholamines, 107
avoidance
p-chloroamphetamine
serotonin release
Catheterization, 147
decapitation
plasma electrolytes
stress
Cathinone, 355
amphetamine
aversion
operant behavior
rate-dependency
CGS 8216
agonist/antagonist, 637
benzodiazepines, 33
chlordiazepoxide, 33
drug interactions, 33
CGS 9896, 637
quantitative autoradiography, 637
social interaction, 33
CGS 9896, 637
agonist/antagonist
CGS 8216
quantitative autoradiography
Chemosensory cues, 289
cigarette smoking
conditioned reinforcement
human studies
satiation
Chlordiazepoxide
acquisition, 487
aversive brain stimulation, 1069
avoidance, 231
benzodiazepines, 33
CGS 8216, 33
clozapine, 231
discrimination, 487
drug comparisons, 231
drug discrimination, 927
drug interactions, 33, 927
escape, 231
ethanol, 927
haloperidol, 231
IC injections, 1069
morphine, 1069
social interaction, 33
p-Chloroamphetamine, 107
avoidance
catecholamines
serotonin release
Cholinergic neurons, 125
lesions, nucleus basalis
memory
recovery of function
Chronic drug treatment, 949
amphetamine
drug discrimination
haloperidol
Cigarette smoking, 289
chemosensory cues
conditioned reinforcement
human studies
satiation
Circadian rhythm
genetic differences, 91
glucose-preference test, 917
lesions, ventromedial hypothalamic, 917
methamphetamine, chronic, 917
pain sensitivity, 91
withdrawal, 917
CL 218,872, 169
drug interaction
hyperphagia
phenobarbital
tracazolate
zopiclone
Climbing, 555
apomorphine
locomotor activity
inbred mice
Clinical blood chemistry, 401
behavioral audiometry
toulene/alcohol interaction
Clonidine
cocaine, 529
dependence, 995
developmental psychopharmacology, 567
discriminative stimulus, 529
fixed-interval schedule, 995
malnutrition, 567
monkeys, 995
α-2 receptors, 529
tolerance, 995
Clorgyline, 921
apomorphine
drug interaction
pargyline
[³H]spiroperidol binding
stereotypy
Clozapine, 231
avoidance
chlordiazepoxide
drug comparisons
escape
haloperidol
CNS binding, 1059
abstinence
morphine dependence
Cocaine
clonidine, 529
convulsion, 573
discriminative stimulus, 529
drug interaction, 823
heroin, 1029
kindling, 573
lesions, kainic acid, 1029
lesions, nucleus accumbens, 1029
local anesthetics, 831
locomotor activity, 831
monkeys, 823
pentylenetetrazol, 573
phencyclidine, 823
α-2 receptors, 529
repeated acquisition, 823
self-administration, 1029
sensitization, 573
sodium channels, 831
Cold water swim, 749
analgesia
desipramine
pain
Compound IV, 645
animal models
anxiolytic activity
phenylpiperazines
Conditioned avoidance response, 1013
gerbils
psychoactive drugs
strain differences
Conditioned flavor aversion, 583
conditioned responses, chin rub
conditioned taste aversion
drug interaction
Conditioned reinforcement, 289
chemosensory cues
cigarette smoking
human studies
satiation
Conditioned responses, chin rub, 583
conditioned flavor aversion
conditioned taste aversion
drug interaction
Conditioned taste aversion
antiemetics, 259
cancer chemotherapy, 259
conditioned flavor aversion, 583
conditioned responses, chin rub, 583
drug interaction, 583
Constant illumination, 535
endogenous opioids
lordosis

Continuous non-match, 599
discrimination
pesticides
working memory
Convulsants, 285
barbiturates
benzodiazepines
GABAergic transmission
Convulsions
cocaine, 573
electroshock, 473
[^{3}H]-flunitrazepam binding, 965
kindling, 573
pentylenetetrazol, 573
phenobarbital, 473
β-phenylethylamine, 965
phenytoin, 473
postnatal development, 473
sensitization, 573
Corticotropin releasing factor, 303
amphetamine
caffeine
heroin
locomotor activity
Cross-generalization, 425
drug discrimination
methylanthines

DA receptor supersensitivity, 715
haloperidol
locomotor activity
Decapitation, 147
catheterization
plasma electrolytes
stress
2-Deoxy-D-glucose, 391
food deprivation
hyperphagia
insulin
NaCl imbibition
Dependence, 995
clonidine
fixed-interval schedule
monkeys
tolerance
Depression, 21
human studies, mentally retarded
hypothalamic-pituitary-adrenal axis
MSH/ACTH fragments
stress
Desipramine
analgesia, 749
bulbectomy, 65
cold water swim, 749
5,7-dihydroxytryptamine, 65
ECS, 65
locus coeruleus, 65
muricide, 65
6-OHDA, 65
pain, 749
substantia nigra, 65
Developmental psychopharmacology, 567
clonidine
malnutrition
Diazepam, 17
aggression
benzodiazepine-receptor
isolation
5,7-Dihydroxytryptamine, 65
bulbectomy
desipramine
ECS
locus coeruleus
muricide
6-OHDA
substantia nigra
Discrimination
acquisition, 487
chlordiazepoxide, 487
continuous non-match, 599
drug interaction, 591
pesticides, 591, 599
spatial reversals, 591
working memory, 591, 599
Discriminative stimulus
clonidine, 529
cocaine, 529
DOM, 937
α-2 receptors, 529
stimulus antagonist, 937
Distal visual cues, 1
anticholinergic drugs
scopolamine
spatial memory
Dogs, 317
pyrazoloquinolines
route of administration
schedule-controlled behavior
DOM, 937
discriminative stimulus
stimulus antagonism
DOPAC/DA ratio, 253
food related stimuli
schedule-induced feeding
Dopamine agonists, 7
drug discrimination
fenfluramine
Dopamine receptor blockade, 243
bombesin
locomotor activity
mediation
Dopamine receptors
adrenergic receptors, 495
cataleptic behavior, 789
exercise, 495
head-twitches, 43
locomotor activity, 43
methiothepin, 43
operant behavior, 495
quipazine, 43
running, 495
stereotyped behavior, 789
Dopaminergic agents, 445
locomotor activity
strain differences
Drinking
aversion, 559
human studies, 559
naloxone, 1065
putative satiety glycoprotein, 559
satietin, 559
tolerance, 1065
Drug
alcohol, 401, 959
amitryptyline, 541
amphetamine, 7, 37, 99, 173, 303, 355, 373, 425, 445, 499, 911
d-amphetamine, 417, 479, 519, 715
apomorphine, 7, 43, 259, 445, 583, 555, 911, 921
atropine, 781, 969
bethanechol, 969
bicuculline, 675
bromazepam, 249
buprenorphine, 1037
busipirone, 687
caffeine, 85, 237, 275, 303, 425, 499, 515, 633
calmodulin, 627
cannabidiol, 13
cannabinol, 13
carbaryl, 591, 599
3-carboethoxy-β-carboline, 17
cathinone, 355
CGS 8216, 33, 317, 637
CGS 9895, 317
CGS 9896, 317, 937
p-chloroamphetamine, 107
chlordiazepoxide, 33, 169, 231, 487, 591, 599, 927, 965, 1069
chlordimeform, 591, 599
chlorimipramine, 541
3-chlorophenylpiperazine, 137
chlorpromazine, 479, 1013
citalopram, 753
CL 218,872, 169
clomipramine, 153
clonazepam, 169, 285
clonidine, 529, 541, 567, 995
clorgyline, 921
clozapine, 203, 231, 479
cocaine, 449, 529, 573, 823, 831, 1013, 1029
CP-52,215, 937
p-CPA, 279
cyclophosphamide, 259
l-cycloserine, 697
DAGO, 871
deltamethrin, 591, 599
2-deoxy-D-glucose, 701
desipramine, 65, 749
dexamethasone, 697
diazepam, 17, 249, 285, 317, 965, 1013
3,4-dihydroxyphenylacetic acid, 253
5,7-dihydroxytryptamine, 65, 473
DOM, 937
l-DOPA, 715
dopamine, 7, 253, 417, 495, 627, 803, 911
DSP-4, 93
eserine, 583
ethanol, 71, 221, 285, 309, 627, 759, 927
ethosuximide, 469
ethylketocyclazocine, 457
fencamfamine, 449
fenfluramine, 7, 509, 551
fluoxetine, 753
flunitrazepam, 637
fluphenazine, 243
flutamide, 397
gammahydroxybutyric acid, 185
glucose, 37
l-glutamic acid-γ-hydrazine, 697
guanethidine, 55, 267
halazepam, 973
haloperidol, 43, 231, 479, 715, 777, 789, 803, 911, 949, 1013
heroin, 303, 411, 495, 499, 1029
histidine, 721
5-HTP, 279
6-hydroxydopamine, 65, 243, 473
l-5-hydroxytryptophan, 43
imipramine, 203
insulin, 391, 701, 709
lead, 49

levomepromazine, 203
levonantradol, 259
lidocaine, 573
lisuride, 461, 937
lithium, 145
LSD, 619
LY-53,857, 937
marihuana, 765
mecamylamine, 781
6-MeO-THBC, 753
methamphetamine, 781, 917, 1013
methiothepin, 43
methscopolamine, 583
methylnaloxonium, 411
methyl naloxonium chloride, 495
methylphenidate, 77, 379
methysergide, 355
metrazol, 425
MHPG-SO_4, 379
MJ-13980, 789
molindone, 911
morphine, 295, 349, 431, 457, 505, 727, 731, 843, 863, 931, 1013, 1045, 1059, 1069
nabilone, 259
naloxone, 13, 199, 207, 345, 431, 499, 535, 769, 797, 883, 905, 1065
naltrexone, 207, 385, 505, 701, 709, 731, 797
neostigmine, 583
nicotine, 141, 279, 289, 325, 439, 851, 987
noradrenaline, 379
norcocaine, 831
norepinephrine, 215, 431, 495, 627, 749
octopamine, 965
Org 2766, 1019
8-OH DPAT, 937
oxaprotiline, 93
pargyline, 921
pentobarbital, 249, 285, 505, 759, 1013
pentylenetetrazol, 573
pergolide, 445
pergolide mesylate, 161
phencyclidine, 99, 607, 613, 743, 803, 823, 1051
phenylacetic acid, 965
phenobarbital, 21, 169, 215, 473
phenylethanolamine, 965
β-phenylethylamine, 519
phenytoin, 473
phosphoramidon, 385
physostigmine, 339, 583, 599, 781, 1013
picrotoxin, 675
pilocarpine, 1013
pimozide, 777
PK 11195, 737
proadifen, 137
prochlorperazine, 259
propoxur, 591, 599
propranolol, 27
(+)-pseudocaine, 831
puromycin, 27
quazepam, 973
quipazine, 43, 943
ritanserin, 937
RO5-4864, 285
Ro 15-1788, 17, 249
scopolamine, 1, 583, 591
serotonin, 417, 627
soman, 225, 1003
streptomycin sulfate, 525
sulbutiamine, 195
sulpiride, 479
suriclone, 653
THC, 607, 1051
Δ-9-THC, 13, 153, 259
theophylline, 425
thioridazine, 203, 479
THT, 937
tifluadom, 979
toluene, 401
tracazolate, 169, 675
trazodone, 137
trifluoperazine, 627, 777
tropacocaine, 831
tryptamine, 943
tryptophan hydroxylase, 215
tyramine, 965
U-50488, 871
valproic acid, 469
verapamil, 969
W-7: [N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide], 627
xylamine, 619
yohimbine, 529
zopiclone, 169, 653
Drug comparisons, 231
  avoidance
  chlordiazepoxide
  clozapine
  escape
  haloperidol
Drug discrimination
  amphetamine, 949
  biodisposition, 607
  chlordiazepoxide, 927
  chronic drug treatment, 949
  cross-generalization, 425
  dopamine agonists, 7
  drug interactions, 927
  ethanol, 927
  fencamfamine, 449
  fenfluramine, 7
  haloperidol, 949
  methylanthines, 425
  phencyclidine, 607
  schedule-controlled responding, 449
  smoking, 607
Drug interaction
  acquisition, 1051
  apomorphine, 921
  benzodiazepines, 33
  caffeine, 633
  CGS 8216, 33
  chlordiazepoxide, 33, 927
  CL 218,872, 169
  clorgyline, 921
  cocaine, 823
  conditioned flavor aversion, 583
  conditioned responses, chin rub, 583
  conditioned taste aversion, 583
  discrimination, 591
  drug discrimination, 927
  ethanol, 759, 927
  hyperphagia, 169
  monkeys, 249, 823, 1051
  monoamine oxidase, 753
  pargyline, 921
  pentobarbital, 759
  pesticides, 591
  phencyclidine, 823
  phenobarbital, 169
  repeated acquisition, 823
  RO 15-1788, 249
  seizures, audiogenic, 753
  self-administration, 759
  serotonin uptake, 753
  social interaction, 33
  spatial reversals, 591
  [^{3}H]spiroperidol binding, 921
  stereotypy, 921
  THC, 1051
  tolerance, 633
  tracazolate, 169
  wheelrunning, 633
  working memory, 591
  zopiclone, 169
Drug reinforcement, 837
  heroin
  intracranial self-stimulation
  self-administration
Drug sensitivity, 191
  exercise
DSIP, 953
  brain temperature
  sleep-promoting substances
DSP-4, 93
  locus coeruleus
  neophobia
  REM sleep deprivation

Eating
  anorexia, 161
  aversion, 559
  body weight, 161
  buprenorphine, 1037
  carbohydrates, 721
  drug interaction, 249
  endorphins, 889
  exercise, 701, 709
  histidine, 721
  human studies, 559
  hyperphagia, 345, 889
  hypothalamic injections, 431
  kappa agonists, 889
  lactation, 345
  monkeys, 249, 1037
  morphine, 431
  naloxone, 345, 431
  opiate antagonists, 889
  opiates, 345
  opioid modulation, 709, 710
  pergolide mesylate, 161
  protein, 721
  putative satiety glycoprotein, 559
  RO 15-1788, 249
  satietin, 559
  satiety, 889
Electric shock, 769
  analgesia
  motor suppression
  opioid peptides
Electroconvulsive shock (ECS), 65
  bulbectomy
  desipramine
  5,7-dihydroxytryptamine
  locus coeruleus
  muricide
  6-OHDA
  substantia nigra
Electroencephalography, 661
  GABA receptor complex
  rabbits
Electroshock, 473

convulsions
phenobarbital
phenytoin
postnatal development
Endogenous opioids, 535
constant illumination
lordosis
β-Endorphin, 141
hypothalamus
neuropeptides
nicotine
Endorphins
aversion, 877
behavior, 857
eating, 889
exercise, 857
hyperphagia, 889
kappa agonist, 889
opiate antagonists, 889
opioids, 877
reward, 877
satiety, 889
self-administration, 877
Enkephalinase inhibition, 385
grooming
opiate withdrawal
REM sleep deprivation
Enkephalins, 207
basal ganglia
bodily asymmetry
rotational behavior
Erythrocytes, 145
human studies
isotope effect
lithium
mania
Escape
avoidance, 225, 231
chlordiazepoxide, 231
clozapine, 231
drug comparisons, 231
haloperidol, 231
soman, 225
Essential fatty acids, 71
alcohol withdrawal
ethanol
prostaglandins
Estrogen, 397
female sexual behavior in male rats
prenatal exposure, antiandrogen
Estrous cyclicity, 221
ethanol
luteinizing hormone levels
prolactin levels
Ethanol
alcohol withdrawal, 71
chlordiazepoxide, 927
drug discrimination, 927
drug interactions, 759, 927
essential fatty acids, 71
estrous cyclicity, 221
luteinizing hormone levels, 221
pentobarbital, 759
prolactin levels, 221
prostaglandins, 71
self-administration, 759
Ethanol-induced sleep, 627
calcium
calmodulin antagonists
Ethanol intake, 333
lesions, amygdala
neophobia
Ethanol sensitivity, 309
body temperature
sex differences, mice
Ethanol withdrawal tremor, 339
physostigmine
Ether stress, 697
GABA catabolism
post mortem changes
Ethological analysis, 979
social investigation
tifluadom
Ethosuximide, 469
fixed-ratio schedule
pigeons
valproic acid
Ethylketocyclazocine, 457
abstinence syndrome
morphine
Exercise
adrenergic receptors, 495
behavior, 857
dopamine receptors, 495
drug sensitivity, 191
eating, 701, 709
endorphins, 857
operant behavior, 495
opioid modulation, 701, 709
running, 495
Exploration
animal model, 461
pCPA, 279
hallucinogens, 461
hyperactivity, 279
locomotor activity, 461

Female sexual behavior in male rats, 397
estrogen
prenatal exposure, antiandrogen
Fencamfamine, 449
drug discrimination
schedule-controlled responding
Fenfluramine
anorexia, 551
body weight, 551
brown adipose tissue, 509
dopamine agonists, 7
drug discrimination, 7
GDP-binding, 509
tolerance, 551
Fetus development, 439
nicotine
prenatal exposure, nicotine
saccharin preferences
Fighting behavior, 237
benzodiazepines
caffeine
Fixed-interval schedule, 995
clonidine
dependence
monkeys
tolerance
Fixed-interval self-stimulation, 519
d-amphetamine
lateral hypothalamus
β-phenylethylamine
Fixed ratio responding, 797
brain self-stimulation
locomotor activity
opioid antagonists
Fixed ratio schedule
amphetamine, 417
ethosuximide, 469
pigeons, 469
thermal stressors, 417
valproic acid, 469
[^{3}H]-Flunitrazepam binding, 965
convulsions
β-phenylethylamine
Food deprivation, 391
2-deoxy-D-glucose
hyperphagia
insulin
NaCl imbibition
Food related stimuli, 253
DOPAC/DA ratio
schedule-induced feeding
Food reward, 199
acquisition
naloxone
opioids
self-stimulation
Forced lever, 781
atropine
mecamylamine
methamphetamine
motor control
physostigmine
Forced swimming test, 203
imipramine
neuroleptics

GABA benzodiazepine receptor complex, 671
benzodiazepine receptor agonists
binding studies
inverse benzodiazepine agonists
GABA catabolism, 697
ether stress
post mortem changes
GABA receptor complex, 661
electroencephalography
rabbits
GABAergic transmission, 285
barbiturates
benzodiazepines
convulsants
R05-4864
Gammahydroxybutyric acid, 185
locomotor activity
neonatal rats
Gastric emptying, 969
stress, cold-restraint
vagal activity
GDP-binding, 509
brown adipose tissue
fenfluramine
Genetic differences, 91
circadian rhythms
pain sensitivity
Gerbils, 1013
conditioned avoidance response
psychoactive drugs
strain differences
Glucose-preference test, 917
circadian rhythm
lesions, ventromedial hypothalamic
methamphetamine, chronic
withdrawal
Grooming, 385
enkephalinase inhibition
opiate withdrawal
REM sleep deprivation

Guanethidine
penile reflexes, 55
sexual behavior, male rat, 55
sociosexual behavior, 267
sympathectomy, 267

Hormone
ACTH 4–9, 367
luteinizing hormone, 55, 221, 765
progesterone, 501
prolactin, 221
prostaglandin, 71
testosterone, 55
Haemolymph, 525
insects
streptomycin sulfate
tissues
Hallucinogens, 461
animal model
exploration
locomotor activity
Haloperidol
amphetamine, 949
avoidance, 231
brain stimulation reward, 777
catalepsy, 911
chlordiazepoxide, 231
chronic drug treatment, 949
clozapine, 231
DA receptor supersensitivity, 715
drug comparisons, 231
drug discrimination, 949
escape, 231
locomotor activity, 715
molindone, 911
neuroleptics, 911
phencyclidine, 803
pimozide, 777
self-stimulation, 777
stereotyped behavior, 803
trifluoperazine, 777
Head-twitches, 43
dopamine receptors
locomotor activity
methiothepin
quipazine
Heart rate, 325
body temperature
nicotine effects
startle response
Y-maze
Heroin
amphetamine, 303, 499
caffeine, 303, 499
cocaine, 1029
corticotropin releasing factor, 303
drug reinforcement, 837
hyperactivity, 411
intracranial self-stimulation, 837
lesions, kainic acid, 1029
lesions, nucleus accumbens, 1029
locomotor activity, 303, 411, 499
methylnaloxonium, 411
methyl naloxonium chloride, 495
naloxone, 499
self-administration, 495, 837, 1029
Heterogeneity, 681
benzodiazepines
binding sites
High-affinity site, 987
low affinity site
nicotine binding
very high affinity site
Hippocampal cholinergic activity, 195
learning and memory
sulbutiamine
thiamine deficiency
Hippocampal theta rhythm, 489
septal stimulation
tyrosine hydroxylase
Histamine, 153
Δ^9-THC
tolerance
withdrawal
Histidine, 721
carbohydrates
eating
protein
Holeboard, 479
neuroleptic drug screening
stereotyped behaviors
Human studies
aversion, 559
chemosensory cues, 289
cigarette smoking, 289
conditioned reinforcement, 289
drinking, 559
eating, 559
erythrocytes, 145
isotope effect, 145
lithium, 145
mania, 145
putative satiety glycoprotein, 559
satiation, 289
satietin, 559
Human studies, mentally retarded, 21
depression
hypothalamic-pituitary-adrenal axis
MSH/ACTH fragments
stress
Human studies, women, 765
luteinizing hormone
marihuana
menopause
6-Hydroxydopamine (6-OHDA), 65
bulbectomy
desipramine
5,7-dihydroxytryptamine
ECS
locus coeruleus
muricide
substantia nigra
Hyperactivity
exploration, 279
heroin, 411
locomotor activity, 411
methylnaloxonium, 411
methylphenidate, 77
operant behavior, 77
pCPA, 279
rate-dependency, 77
Hyperphagia
CL 218,872, 169
2-deoxy-D-glucose, 391
drug interaction, 169
eating, 345, 889
endorphins, 889
food deprivation, 391
insulin, 391
Kappa agonists, 889
lactation, 345
NaCl imbibition, 391
naloxone, 345
opiate antagonists, 889
opiates, 345
phenobarbital, 169
satiety, 889
tracazolate, 169
zopiclone, 169
Hyperthermia, 373
inbred mice
thermoregulation
Hypothalamic injections, 431
morphine
naloxone
Hypothalamic-pituitary-adrenal axis, 21
depression
human studies, mentally retarded
MSH/ACTH fragments
stress
Hypothalamus, 141
β-endorphin
neuropeptides
nicotine

IC injections, 1069
aversive brain stimulation
chlordiazepoxide
morphine
Imipramine, 203
forced swimming test
neuroleptics
Inbred mice
apomorphine, 555
caffeine-induced lethality, 275
climbing, 555
hyperthermia, 373
locomotor activity, 555
pharmacogenetics, 275
thermoregulation, 373
Inhibition, 137
avoidance
metabolism
trazodone
Insects, 525
haemolymph
streptomycin sulfate
tissues
Insulin, 391
2-deoxy-D-glucose
food deprivation
hyperphagia
NaCl imbibition
Intracerebroventricular administration, 731
pigeons
Intracranial self-stimulation, 837
drug reinforcement
heroin
self-administration
Inverse benzodiazepine agonists, 671
benzodiazepine receptor agonists
binding studies
GABA benzodiazepine receptor complex
Isolation, 17
aggression
benzodiazepine-receptor
diazepam
Isotope effect, 145
erythrocytes
human studies
lithium
mania

Kappa agonists, 889
eating
endorphins
hyperphagia
opiate antagonists
satiety
Ketamine, 743
baboons
phencyclidine
reaction times
sensory thresholds
Kindling
alcohol, 959
anticonvulsant, 959
cocaine, 573
convulsion, 573
pentylenetetrazol, 573
sensitization, 573
tolerance, 959

Lactation, 345
eating
hyperphagia
naloxone
opiates
Lateral hypothalamus
d-amphetamine, 519
fixed-interval self-stimulation, 519
median raphe nucleus, 943
β-phenylethylamine, 519
quipazine, 943
self-stimulation, 943
tryptamine, 943
Lead, 49
aging
passive avoidance
Learning and memory, 195
hippocampal cholinergic activity
sulbutiamine
thiamine deficiency
Lesions, amygdala, 333
ethanol intake
neophobia
Lesions, central medial nucleus accumbens, 843
morphine
neurotransmitter content
self-administration
Lesions, hippocampal, 1019
attention
lesions, neocortical
lesions, sham
Org 2766
Lesions, kainic acid, 1029
cocaine
heroin
lesions, nucleus accumbens
Lesions, neocortical, 1019
attention
lesions, hippocampal
lesions, sham
Org 2766
Lesions, nucleus accumbens, 1029
cocaine
heroin
lesions, kainic acid
self-administration
Lesions, nucleus basalis, 125
cholinergic neurons
memory
recovery of function
Lesions, sham, 1019
attention
lesions, hippocampal
lesions, neocortical
Org 2766
Lesions, ventromedial hypothalamic, 917
circadian rhythm
glucose-preference test
methamphetamine, chronic withdrawal
Lipid metabolism, 811
antiobesity drugs
carbohydrate absorption
meal patterns
Lithium, 145
erythrocytes
human studies
isotope effect
mania
Local anesthetics, 831
cocaine
locomotor activity
sodium channels
Locomotor activity
amphetamine, 99, 303, 499
animal model, 461
apomorphine, 555
bombesin, 243
brain self-stimulation, 797
caffeine, 85, 303, 499, 515
climbing, 555
cocaine, 831
corticotropin releasing factor, 303
DA receptor supersensitivity, 715
dopamine receptor blockade, 243
dopamine receptors, 43
dopaminergic agents, 445
exploration, 461
fixed ratio responding, 797
gammahydroxybutyric acid, 185
hallucinogens, 461
haloperidol, 715
head-twitches, 43
heroin, 303, 411, 499
hyperactivity, 411
inbred, 555
local anesthetics, 831
LSD, 619
mediation, 243
methiothepin, 43
methylnaloxonium, 411
mimetic responses, 515
naloxone, 499
neonatal rats, 185
neophobia, 515, 619
norepinephrine, 619
opioid antagonists, 797
phencyclidine, 99
quipazine, 43
sodium channels, 831
spatial learning, 85
stereotypy, 99
strain differences, 445
taste aversion, 515
tunnel maze, 85
xylamine, 619
Locus coeruleus
bulbectomy, 65
desipramine, 65
5,7-dihydoxytryptamine, 65
DSP-4, 93
ECS, 65
muricide, 65
neophobia, 93
6-OHDA, 65
REM sleep deprivation, 93
substantia nigra, 65
Lordosis, 535
constant illumination
endogenous opioids
Lordosis response, 501
adenylate cyclase
cAMP
progesterone
Low affinity site, 987
high affinity site
nicotine binding
very high affinity site
LSD, 619
locomotor activity
neophobia
norepinephrine
tylamine
Luteinizing hormone, 765
human studies, women
marihuana
menopause
Luteinizing hormone levels, 221
estrous cyclicity
ethanol
prolactin levels

Magnetic fields, 727
opioid-induced feeding
slugs
Malnutrition, 567
clonidine
developmental psychopharmacology
Mania, 145
erythrocytes
human studies
isotope effect
lithium
Marihuana, 765
human studies, women
luteinizing hormone
menopause
Meal patterns, 811
antiobesity drugs
carbohydrate absorption
lipid metabolism
Mecamylamine, 781
atropine
forced lever
methamphetamine
motor control
physostigmine
Median raphe nucleus, 943
lateral hypothalamus
quipazine
self-stimulation
tryptamine
Mediation, 243
bombesin
dopamine receptor blockade
locomotor activity
Memory
aversion, 37
cholinergic neurons, 125
lesions, nucleus basalis, 125
place preference, 37
recovery of function, 125

Memory spread, 27
β-adrenergic antagonist
propranolol
Menopause, 765
human studies, women
luteinizing hormone
marihuana
Metabolism, 137
avoidance
inhibition
trazodone
Methamphetamine, 781
atropine
forced lever
mecamylamine
motor control
physostigmine
Methamphetamine, chronic, 917
circadian rhythm
glucose-preference test
lesions, ventromedial hypothalamic
withdrawal
Methiothepin, 43
dopamine receptors
head-twitches
locomotor activity
quipazine
Method
autoradiography, 637, 681
cold-restraint stress, 969
dexamethasone suppression test, 21
electroencephalography, 661
gel filtration, 1045
high performance liquid chromatography, 1045, 1065
photo affinity labeling, 681
quantitative autoradiography, 27
radioimmunoassay, 1045
Methylanthines, 425
cross-generalization
drug discrimination
Methylnaloxonium, 411
heroin
hyperactivity
locomotor activity
Methylnaloxonium chloride, 495
heroin
self-administration
Methylphenidate
brain metabolism, 379
hyperactivity, 77
operant behavior, 77
rate-dependency, 77
stress, 379
ulcer, 379
Mimetic responses, 515
caffeine
locomotor activity
neophobia
taste aversion
Molindone, 911
catalepsy
haloperidol
neuroleptics
Monkeys
acquisition, 1051
buprenorphine, 1037
clonidine, 995
cocaine, 823
dependence, 995
drug interaction, 249, 823, 1051
eating, 1037
fixed-interval schedule, 995
phencyclidine, 823
repeated acquisition, 823
RO 15-1788, 249
THC, 1051
tolerance, 995
Monoamine neurotransmitters, 215
barbiturates
phenobarbital
Monoamine oxidase, 753
drug interaction
seizures, audiogenic
serotonin uptake
Morphine
abstinence syndrome, 457
analgesia, 931
aversive brain stimulation, 1069
body temperature, 505
brain stimulation electrical, 931
chlordiazepoxide, 1069
ethylketocyclazocine, 457
hypothalamic injections, 431
IC injections, 1069
lesions, central medial nucleus accumbens, 843
naloxone, 431
narcosis, 505
neurotransmitter content, 843
opiate dependence, 863
opiate withdrawal, 863
pentobarbital, 505
receptor binding, 349
self-administration, 843
strain differences, 349
Morphine cross tolerance, 883
analgesia
naloxone
social conflict
Morphine dependence, 1059
abstinence
CNS binding
Morphine pharmacokinetics, 295
muscular rigidity
nucleus accumbens
striatum
Motor control, 781
atropine
forced lever
mecamylamine
methamphetamine
physostigmine
Motor suppression, 769
analgesia
electric shock
opioid peptides
MSH/ACTH fragments, 21
depression
human studies, mentally retarded
hypothalamic-pituitary-adrenal axis
stress
Muricide, 65
bulbectomy
desipramine
5,7-dihydroxytryptamine
ECS
locus coeruleus
6-OHDA
substantia nigra
Muscular rigidity, 295
morphine pharmacokinetics
nucleus accumbens
striatum
NaCl imbibition, 391
2-deoxy-D-glucose
food deprivation
hyperphagia
insulin
Naloxone
acquisition, 199
amphetamine, 499
analgesia, 883
caffeine, 499
cannabidiol, 13
cannabinol, 13
drinking, 1065
eating, 345
food reward, 199
heroin, 499
hyperphagia, 345
hypothalamic injections, 431
lactation, 345
locomotor activity, 499
morphine, 431
morphine cross tolerance, 883
open field, 905
opiates, 345
opioids, 199
quasi-morphine withdrawal syndrome, 13
self-stimulation, 199
social behavior, 905
social conflict, 883
Δ-9-THC, 13
tolerance, 1065
Narcosis, 505
body temperature
morphine
pentobarbital
Neonatal rats, 185
gammahydroxybutyric acid
locomotor activity
Neophobia
caffeine, 515
DSP-4, 93
ethanol intake, 333
lesions, amygdala, 333
locomotor activity, 515, 619
locus coeruleus, 93
LSD, 619
mimetic responses, 515
norepinephrine, 619
REM sleep deprivation, 93
taste aversion, 515
xylamine, 619
Neurobehavioral response, 1003
baboons
seizures
soman, sublethal exposure
Neuroleptic drug screening, 479
holeboard
stereotyped behaviors
Neuroleptics
catalepsy, 911
forced swimming test, 203
haloperidol, 911
imipramine, 203
molindone, 911
Neuropeptides, 141
β-endorphin
hypothalamus
nicotine
Neurotransmitter content, 843
lesions, central medial nucleus accumbens

morphine
self-administration
Nicotine
body weight, 851
caloric expenditure, 851
β-endorphin, 141
fetus development, 439
hypothalamus, 141
neuropeptides, 141
physical activity, 851
prenatal exposure, nicotine, 439
saccharin preferences, 439
Nicotine binding, 987
high affinity site
low affinity site
very high affinity site
Nicotine effects, 325
body temperature
heart rate
startle response
Y-maze
Nonbenzodiazepine, 687
anxiety
busipirone
Norepinephrine, 619
locomotor activity
LSD
neophobia
xylamine
Nucleus accumbens, 295
morphine pharmacokinetics
muscular rigidity
striatum

Open field, 905
naloxone
social behavior
Operant behavior
adrenergic receptors, 495
amphetamine, 355
aversion, 355
cathinone, 355
dopamine receptors, 495
exercise, 495
hyperactivity, 77
methylphenidate, 77
rate-dependency, 77, 355
running, 495
Opiate antagonists, 889
eating
endorphins
hyperphagia
Kappa agonists
satiety
Opiate dependence, 863
opiate withdrawal
morphine
Opiate receptors, 871
aggression
social interaction
Opiates, 345
eating
hyperphagia
lactation
naloxone
Opiate withdrawal
enkephalinase inhibition, 385
grooming, 385
morphine, 863
opiate dependence, 863
REM sleep deprivation, 385
Opioid antagonists, 797
brain self-stimulation
fixed ratio responding
locomotor activity
Opioid-induced feeding, 727
magnetic fields
slugs
Opioid modulation
eating, 701, 709
exercise, 701, 709
Opioid peptides, 769
analgesia
electric shock
motor suppression
Opioids
acquisition, 199
aversion, 877
endorphins, 877
food reward, 199
naloxone, 199
reward, 877
self-administration, 877
self-stimulation, 199
Org 2766, 1019
attention
lesions, hippocampal
lesions, neocortical
lesions, sham

Pain, 749
analgesia
cold water swim
desipramine
Pain sensitivity, 91
circadian rhythms
genetic differences
Paraventricular nucleus, 541
α-adrenergic agonist
antidepressants
carbohydrate ingestion
Pargyline, 921
apormorphine
clorgyline
drug interaction
[^{3}H]spiroperidol binding
stereotypy
Passive avoidance, 49
aging
lead
pCPA, 279
exploration
hyperactivity
Penile reflexes, 55
guanethidine
sexual behavior, male rat
Pentobarbital
body temperature, 505
drug interaction, 759
ethanol, 759
morphine, 505
narcosis, 505
self-administration, 759
Pentylenetetrazol, 573
cocaine
convulsion
kindling
sensitization
Peptide
bombesin, 243
corticotropin releasing factor (CRF), 303
delta sleep-inducing peptide, 953
β-endorphin, 141, 535
met^5-enkephalin, 141
enkephalins, 207
Pergolide mesylate, 161
anorexia
body weight
eating
Perseveration, 173
amphetamine
stress
Pesticides
continuous non-match, 599
discrimination, 591, 599
drug interaction, 591
spatial reversals, 591
working memory, 591, 599
Pharmacogenetics, 275
caffeine-induced lethality
inbred mice
Pharmacological studies, 653
suriclone
zopiclone
Phencyclidine
amphetamine, 99
baboons, 743
biodisposition, 607
calcium channel inhibitors, 613
cocaine, 823
drug discrimination, 607
drug interaction, 823
haloperidol, 803
ketamine, 743
locomotor activity, 99
monkeys, 823
reaction times, 743
repeated acquisition, 823
sensory thresholds, 743
smoking, 607
stereotyped behavior, 803
stereotypy, 99
stimulation, 613
Phenobarbital
barbiturates, 215
CL 218,872, 169
convulsions, 473
drug interaction, 169
electroshock, 473
hyperphagia, 169
monoamine neurotransmitters, 215
phenytoin, 473
postnatal development, 473
tracazolate, 169
zopiclone, 169
β-Phenylethylamine
d-amphetamine, 519
convulsions, 965
fixed-interval self-stimulation, 519
[^{3}H]-flunitrazepam binding, 965
lateral hypothalamus, 519
Phenylpiperazines, 645
animal models
anxiolytic activity
compound IV
Phenytoin, 473
convulsions
electroshock
phenobarbital
postnatal development
Physical activity, 851
body weight

caloric expenditure
nicotine
Physostigmine
atropine, 781
ethanol withdrawal tremor, 339
forced lever, 781
mecamylamine, 781
methamphetamine, 781
motor control, 781
Pigeons
ethosuximide, 469
fixed-ratio schedule, 469
intracerebroventricular administration, 731
valproic acid, 469
Pimozide, 777
brain stimulation reward
haloperidol
self-stimulation
trifluoperazine
PK 11195, 737
anxiety
benzodiazepine binding sites
stress
Place preference, 37
aversion
memory
Plasma electrolytes, 147
catheterization
decapitation
stress
Postnatal development, 473
convulsions
electroshock
phenobarbital
phenytoin
Post mortem changes, 697
ether stress
GABA catabolism
Prenatal exposure, antiandrogen, 397
estrogen
female sexual behavior in male rats
Prenatal exposure, nicotine, 439
fetus development
nicotine
saccharin preferences
Progesterone, 501
adenylate cyclase
cAMP
lordosis response
Prolactin levels, 221
estrous cyclicity
ethanol
luteinizing hormone levels
Propranolol, 27
β-adrenergic antagonist
memory spread
Prostaglandins, 71
alcohol withdrawal
essential fatty acids
ethanol
Protein, 721
carbohydrates
eating
histidine
Psychoactive drugs, 1013
conditioned avoidance response
gerbils
strain differences
Putative satiety glycoprotein, 559
aversion
drinking
eating
human studies
satietin
Pyrazolopyridines, 675
anxiolytic activity
tracazolate
Pyrazoloquinolines, 317
dogs
route of administration
schedule-controlled behavior

Quantitative autoradiography, 637
agonist/antagonist
CGS 8216
CGS 9896
Quasi-morphine withdrawal syndrome,
cannabidiol
cannabinol
naloxone
Δ-9-THC
Quipazine
dopamine receptors, 43
head-twitches, 43
lateral hypothalamus, 943
locomotor activity, 43
median raphe nucleus, 943
methiothepin, 43
self-stimulation, 943
tryptamine, 943

Rabbits, 661
electroencephalography
GABA receptor complex
Rate-dependency
amphetamine, 355
aversion, 355
cathinone, 355
hyperactivity, 77
methylphenidate, 77
operant behavior, 77, 355
Route of administration, 317
dogs
pyrazoloquinolines
schedule-controlled behavior
Reaction times, 743
baboons
ketamine
phencyclidine
sensory thresholds
Receptor binding, 349
morphine
strain differences
Receptor sites, 973
autoradiography
benzodiazepines
α-2 Receptors, 529
clonidine
cocaine
discriminative stimulus
Recovery of function, 125
cholinergic neurons
lesions, nucleus basalis
memory
REM sleep deprivation
DSP-4, 93
enkephalinase inhibition, 385
grooming, 385
locus coeruleus, 93
neophobia, 93
opiate withdrawal, 385
Repeated acquisition, 823
cocaine
drug interaction
monkeys
phencyclidine
Reward, 877
aversion
endorphins
opioids
self-administration
RO5-4864, 285
barbiturates
benzodiazepines
convulsants
GABAergic transmission
Ro 15-1788, 249
drug interaction
monkeys
Rotational behavior, 207
basal ganglia
bodily asymmetry
enkephalins
Running, 495
adrenergic receptors
dopamine receptors
exercise
operant behavior

Saccharin preferences, 439
fetus development
nicotine
prenatal exposure, nicotine
Satiation, 289
chemosensory cues
cigarette smoking
conditioned reinforcement
human studies
Satietin, 559
aversion
drinking
eating
human studies
putative satiety glycoprotein
Satiety, 889
eating
endorphins
hyperphagia
Kappa agonists
opiate antagonists
Schedule-controlled behavior, 317
dogs
pyrazoloquinolines
route of administration
Schedule-controlled responding, 449
drug discrimination
fencamfamine
Schedule-induced feeding, 253
DOPAC/DA ratio
food related stimuli
Scopolamine, 1
anticholinergic drugs
distal visual cues
spatial memory
Seizures, 1003
baboons
neurobehavioral response
soman, sublethal exposure
Seizures, audiogenic, 753
drug interaction
monoamine oxidase
serotonin uptake

Self-administration
aversion, 879
cocaine, 1029
drug interaction, 759
drug reinforcement, 837
endorphins
ethanol, 759
heroin, 495, 837, 1029
intracranial self-stimulation, 837
lesions, central medial nucleus accumbens, 843
lesions, kainic acid, 1029
lesions, nucleus accumbens, 1029
methyl naloxonium chloride, 495
morphine, 843
neurotransmitter content, 843
opioids, 879
pentobarbital, 759
reward, 877
Self-stimulation
acquisition, 199
brain stimulation reward, 777
food reward, 199
haloperidol, 777
lateral hypothalamus, 943
median raphe nucleus, 943
naloxone, 199
opioids, 199
pimozide, 777
quipazine, 943
trifluoperazine, 777
tryptamine, 943
Sensitization, 573
cocaine
convulsion
kindling
pentylenetetrazol
Sensory thresholds, 743
baboons
ketamine
phencyclidine
reaction times
Septal stimulation, 489
hippocampal theta rhythm
tyrosine hydroxylase
Serotonin release, 107
avoidance
catecholamines
p-chloroamphetamine
Serotonin uptake, 753
drug interaction
monoamine oxidase
seizures, audiogenic
Sex differences, mice, 309
body temperature
ethanol sensitivity
Sexual behavior, male rat, 55
guanethidine
penile reflexes
Sleep-promoting substances, 953
brain temperature
DSIP
Slugs, 727
magnetic fields
opioid-induced feeding
Smoking, 607
biodisposition
drug discrimination
phencyclidine
Social behavior, 905
open field
naloxone
Social conflict, 883
analgesia
morphine cross tolerance
naloxone
Social interaction
aggression, 871
benzodiazepines, 33
CGS 8216, 33
chlordiazepoxide, 33
drug interactions, 33
opiate receptors, 871
Social investigation, 979
ethological analysis
tifluodom
Sociosexual behavior, 267
guanethidine
sympathectomy
Sodium channels, 831
cocaine
local anesthetics
locomotor activity
Soman, 225
avoidance
escape
Soman, sublethal exposure, 1003
baboons
neurobehavioral response
seizures
Spatial learning, 85
caffeine
locomotor activity
tunnel maze
Spatial memory, 1
anticholinergic drugs
distal visual cues
scopolamine
Spatial reversals, 591
discrimination
drug interaction
pesticides
working memory
[^{3}H]Spiroperidol binding, 921
apomorphine
clorgyline
drug interaction
pargyline
stereotypy
Startle response, 325
body temperature
heart rate
nicotine effects
Y-maze
Stereotyped behavior
cataleptic behavior, 789
dopamine receptors, 789
haloperidol, 803
holeboard, 479
neuroleptic drug screening, 479
phencyclidine, 803
Stereotypy
amphetamine, 99
apomorphine, 921
clorgyline, 921
drug interaction, 921
locomotor activity, 99
pargyline, 921
phencyclidine, 99
[^{3}H]spiroperidol binding, 921
Stimulation, 613
calcium channel inhibitors
phencyclidine
Stimulus antagonism, 937
DOM
discriminative stimulus
Strain differences
conditioned avoidance response, 1013
dopaminergic agents, 445
gerbils, 1013
locomotor activity, 445
morphine, 349
psychoactive drugs, 1013
receptor binding, 349
Streptomycin sulfate, 525
haemolymph
insects
tissues
Stress
amphetamine, 173
anxiety, 737
benzodiazepine binding sites, 737
brain metabolism, 379
catheterization, 147
decapitation, 147
depression, 21
human studies, mentally retarded, 21
hypothalamic-pituitary-adrenal axis, 21
methylphenidate, 379
MSH/ACTH fragments, 21
perseveration, 173
PK 11195, 737
plasma electrolytes, 147
ulcer, 379
Stress, cold-restraint, 969
gastric emptying
vagal activity
Striatum, 295
morphine pharmacokinetics
muscular rigidity
nucleus accumbens
Substantia nigra, 65
bulbectomy
desipramine
5,7-dihydroxytryptamine
ECS
locus coeruleus
6-OHDA
Sulbutiamine, 195
hippocampal cholinergic activity
learning and memory
thiamine deficiency
Suriclone, 653
pharmacological studies
zopiclone
Sympathectomy, 267
guanethidine
sociosexual behavior

Taste aversion, 515
caffeine
locomotor activity
mimetic responses
neophobia
Δ-9-Tetrahydrocannabinol (THC), 13
cannabidiol
cannabinol
naloxone
quasi-morphine withdrawal syndrome
THC, 1051
acquisition
drug interaction
monkeys

Δ-9-THC, 153
histamine
tolerance
withdrawal
Thermal stressors, 417
amphetamine
fixed ratio schedule
Thermoregulation, 373
inbred mice
hyperthermia
Thiamine deficiency, 195
hippocampal cholinergic activity
learning and memory
sulbutiamine
Tifluadom, 979
ethological analysis
social investigation
Tissues, 525
haemolymph
insects
streptomycin sulfate
Tolerance
alcohol, 959
anorexia, 551
anticonvulsant, 959
body weight, 551
caffeine, 633
clonidine, 995
dependence, 995
drinking, 1065
drug interaction, 633
fenfluramine, 551
fixed-interval schedule, 995
histamine, 153
kindling, 959
monkeys, 995
naloxone, 1065
Δ^9-THC, 153
wheelrunning, 633
withdrawal, 153
Toluene/alcohol interaction, 401
behavioral audiometry
clinical blood chemistry
Tracazolate
anxiolytic activity, 675
CL 218,872, 169
drug interaction, 169
hyperphagia, 169
phenobarbital, 169
pyrazolopyridines, 675
zopiclone, 169
Trazodone, 137
avoidance
inhibition
metabolism
Trifluoperazine, 777
brain stimulation reward
haloperidol
pimozide
self-stimulation
Tyr-MIF-1, 1045
analgesia
animal model
antinociception
Tryptamine, 943
lateral hypothalamus
median raphe nucleus
quipazine
self-stimulation
Tunnel maze, 85
caffeine
locomotor activity
spatial learning
Tyrosine hydroxylase, 489
hippocampal theta rhythm
septal stimulation

Ulcer, 379
brain metabolism
methylphenidate
stress

Vagal activity, 969
gastric emptying
stress, cold-restraint
Valproic acid, 469
ethosuximide
fixed-ratio schedule
pigeons
Very high affinity site, 987
high affinity site
low affinity site
nicotine binding

Wheelrunning, 633
caffeine
drug interaction
tolerance
Withdrawal
circadian rhythm, 917
glucose-preference test, 917
histamine, 153
lesions, ventromedial hypothalamic, 917
methamphetamine, chronic, 917
Δ^9-THC, 153
tolerance, 153
Working memory
continuous non-match, 599
discrimination, 591, 599
drug interaction, 591
pesticides, 591, 599
spatial reversals, 591

Xylamine, 619
locomotor activity
LSD
neophobia
norepinephrine

Y-maze, 325
body temperature
heart rate
nicotine effects
startle response

Zopiclone
CL 218,872, 169
drug interaction, 169
hyperphagia, 169
pharmacological studies, 653
phenobarbital, 169
suriclone, 653
tracazolate, 169

AUTHOR INDEX

Adams, J. U., 731
Adams, L. M., 461, 619
Akiyama, K., 627
Alföldi, P., 953
Alkana, R. L., 309
Amalric, M., 411
Amano, M., 803
Anderson, G. H., 721
Anisman, H., 173
Asdourian, D., 207

Balster, R. L., 259, 607, 995
Barnett, A., 973
Barr, T. S., 843
Barrett, R. J., 949
Barron, J., 21
Bartholini, G., 645
Bartus, R. T., 125
Bättig, K., 85, 279
Bealer, S. M., 325
Beatty, W. W., 1
Beer, B., 681
Bellinger, L. L., 559
Benedikt, R., 765
Benton, D., 871, 979
Berman, R. F., 49
Bertolissi, M., 237
Beuthin, F. C., 49
Bierley, R. A., 1
Blackman, D. E., 519
Blanchard, J. C., 653
Bloom, F. E., 495
Boast, C. A., 639
Bodnar, R. J., 749
Boissard, C. G., 93
Boone, D. C., 309
Born, J., 367
Bourbonais, K. A., 253
Bowen, D. J., 851
Bozarth, M. A., 837
Brady, J. V., 743
Brain, P. F., 979
Brandão, M. L., 1069
Bray, G. A., 509
Bree, M. P., 1037
Broadbent, J., 943
Brown, O., 541
Bryant, H. U., 391
Buckholtz, N. S., 753
Buterbaugh, G. G., 473

Cabib, S., 555
Cabral, A. M., 1069
Campbell, I. C., 921
Carlson, K. R., 349, 1059
Carlton, J., 551
Carney, J. M., 191, 275, 373
Carr, G. D., 37
Castellano, C., 91
Caul, W. F., 949
Chen, C., 145
Chesher, G. B., 13
Cho, C. H., 969

Chugani, D., 921
Church, A. C., 27
Clemens, L. G., 397
Co, C., 843
Cohen, R. M., 921
Coleman, G. J., 535
Collado, M. L., 501
Collins, A. C., 325
Conahan, S. T., 147
Cone, E. J., 449
Cook, L., 637
Cooper, D. O., 349, 1059
Cooper, S. J., 169, 889
Copolov, D. L., 535
Coy, D. H., 1045
Cristofaro, P., 765
Cruz, M. L., 501

Dall'Olio, R., 43
Davidson, J. M., 55
Davis, J. M., 701, 709
Dean, R. L., 125
de Angelis, L., 237
de Castro, J. M., 495
Delatte, S. W., 1065
Delini-Stula, A., 93
Della Loggia, R., 237
DeNoble, V. J., 759
Depoortere, H., 645
Destrade, C., 195
Dohanich, G. P., 397
Drewnowski, A., 811
Dreyfus, J. F., 653
Duncan, G., 495
DuPaul, G. J., 77
Durcan, M. J., 921
Durkin, T. P., 195
Dzoljic, M. R., 385

Eison, M. S., 687
Ellingboe, J., 765
Ellis, S., 249
Ellsworth, K. A., 613
Emery, D. E., 267
Emmett-Oglesby, M. W., 529
Ertle, A., 289
Esquifino, A., 221

Fatherazi, S., 505
Fayle, P., 715
Feer, H., 917
Fehm, H. L., 367
Fehm-Wolfsdorf, G., 367
Fennessy, M. R., 153
Figueiredo, J. C., 125
File, S. E., 33, 737
Fillenz, M., 489
Finkelstein, J. A., 7
Finn, D. A., 309
Fischman, A. J., 1045
Fisher, S. K., 125
FitzGerald, R. E., 279
Flexner, J. B., 27
Flexner, L. B., 27
Flicker, C., 125
Foltin, R. W., 249
France, C. P., 731
Freed, W. J., 613
Fuller, R. W., 445
Furukawa, H., 803

Garbin, C. P., 161
Garrett, K. M., 681
Gause, E. M., 225, 1003
Geller, I., 225, 1003
Gerber, G. J., 837
Geula, C., 207
Geyer, M. A., 461, 619
Glavin, G. B., 379
Glennon, R. A., 937
Goldberg, M. E., 675
Golden, J. S., 973
Goodlett, C. R., 567
Gordon, J., 619
Górka, Z., 203
Gosnell, B. A., 345
Gothoni, P., 339
Goudie, A. J., 355
Graham-Jones, S., 489
Gray, J. A., 489
Grebb, J. A., 613
Greenberg, B. D., 99
Greene, S. B., 161
Greenshaw, A. J., 519, 943
Grinker, J. A., 811
Grossett, D., 469
Gruen, R., 811
Grunberg, N. E., 851
Guerin, G. F., 843
Guerri, C., 221

Haenlein, M., 949
Hahn, B., 173
Hajós, M., 953
Hannigan, J. H., Jr., 1019
Harris, L. S., 259
Hartmann, R. J., Jr., 225, 1003
Hauck, A. E., 937
Havemann, U., 295
Hedner, J., 185
Hedner, T., 185
Heise, G. A., 591, 599
Hendrie, C. A., 863
Hendry, J. S., 141
Hernandez, J., 987
Hienz, R. D., 743
Hirsch, J. D., 681
Hoffman, D., 173
Hollingsworth, E. M., 161
Holloway, F. A., 425
Holt, L., 489
Hong, J.-S., 141
Hook, R., 987
Horita, A., 505
Howd, R. A., 401
Hruska, R. E., 789
Hudson, J. D., 591, 599
Hulse, G. K., 535
Hunn, C., 93
Hymson, D. L., 445
Hynes, M. D., 445

Iimura, K., 627
Isaacson, R. L., 1019
Iser, C., 215
Iversen, K., 185

Jackson, A., 889
Jackson, D. M., 13, 715
Jackson-Smith, P. A., 449
Jaffard, R., 195
Janus, K., 203
Jenkins, O. F., 715
Johnson, P., 275, 373
Johnston, S., 243
Julou, L., 653

Kamei, H., 769
Kameyama, T., 769, 803
Karli, P., 931
Karobath, M., 671
Kaston, A. J., 1045, 1065
Kavaliers, M., 727
Kazi, S., 505
Khazan, N., 457
Kirkham, T. C., 889
Kirschgessner, A., 541
Klauenberg, B. J., 417
Klemm, W. R., 911
Kleven, M. S., 417
Kolakowska, L., 333
Koo, M. W. L., 969
Koob, G. F., 303, 411, 495, 499
Kraeuchi, K., 917
Kuribara, H., 1013
Kuschinsky, K., 295

Lafer, R., 289
Lafferty, P. A., 715
Lai, H., 505
Lajtha, A., 831
Lal, H., 529
Lamb, D. R., 701, 709
Landauer, M. R., 259
Landrum, R. E., 633
Lane, J. D., 843
Langer, D. H., 445
Langer, S. Z., 645
Larue-Achagiotis, C., 333
Leal, B. Z., 1003
Lee, V. W. K., 535
Leibowitz, S. F., 431, 541
Le Magnen, J., 333
Levine, A. S., 345
Lewis, S. J., 153
Lichtensteiger, W., 439
Lieberman, K. W., 145
Liou, S. Y., 65
Ljungberg, T., 479
Lloyd, K. G., 645
Loke, W. H., 633
Longo, V., 637
Louis-Ferdinand, R. T., 49
Lovano, D. M., 927
Lowy, M. T., 391, 701
Lukas, S. E., 743, 1037
Lundborg, P., 185
Lupien, J. R., 509
Lynch, M. R., 777

McKearney, J. W., 349
McLean, J. H., 1065
McMaster, S. B., 191
McNaughton, N., 487

Malick, J. B., 675
Malven, P. V., 391
Malven, P. W., 701, 709
Mandio Cordasco, D., 71
Manev, H., 697
Mann, J., 145
Mann, P. E., 749
Manoury, Ph., 645
Marks, M. J., 325
Martin, B. R., 607
Martin, J. R., 85
Martin, W. R., 987
Mason, F. D., 515
Massotti, M., 661
Mathers, A., 727
Mathews, D., 161
Matsuno, K., 769
Meisler, B. E., 831
Melamed, E., 215
Mele, P. C., 759
Meliska, C. J., 633
Mello, N. K., 765, 1037
Melzacka, M., 137, 295
Mendel, V. E., 559
Mendelson, J. H., 765, 1037
Merali, Z., 243
Michael, R. P., 797
Micheau, J., 195
Modrow, H. E., 425
Mogilnicka, E., 93
Montanaro, N., 43
Moores, W. R., 169
Moreau, J.-L., 931
Morgane, P. J., 567
Morley, J. E., 345
Morris, P., 721
Morselli, P. L., 645
Murphy, D. L., 921

Nabeshima, T., 769, 803
Nagel, D. J., 367
Narayan, S., 147
Nardini, G., 237
Neßelhut, T., 295
Noda, Y., 769

Obál, F., Jr., 953
Oettinger, R., 85, 279
Ogle, C. W., 969
Ögren, S.-O., 107
Oliverio, A., 91
Olson, G. A., 1065
Olson, R. D., 1065
Ossenkopp, K.-P., 727

Parker, L., 21
Parker, L. A., 583
Patel, J. B., 675
Paterson, A. T., 905
Paul, S. M., 17
Pearson, D. V., 445
Pellow, S., 33, 737
Penke, B., 953
Peričić, D., 697
Pettit, H. O., 495
Phillpott, D. F., 1065
Pickar, D., 921
Picker, M., 469
Pinel, J. P. J., 959
Poel-Heisterkamp, A. L. v. d., 385
Poling, A., 469
Pontecorvo, M., 125
Porter, J. H., 759
Preston, K. L., 781
Pryor, G. T., 401
Puglisi-Allegra, S., 91, 555
Puttaswamaiah, S., 959

Rainbow, T. C., 27
Randall, J. I., 883
Rapport, M. D., 77
Rastogi, S. K., 285
Reed, G. F., 17
Reith, M. E. A., 831
Rennert, O. M., 275, 373
Renzi, P., 91
Resnick, O., 567
Riblet, L. A., 687
Risner, M. E., 449
Roberts, D. C. S., 1029
Roderick, T. H., 275
Rodgers, R. J., 883
Rodríguez-Manzo, G., 501
Rolland, Y., 195
Romm, E., 325
Rose, J. E., 289
Rosecrans, J. A., 141
Rosen, J. B., 49
Rosenberg, E., 85
Rotrosen, J., 71
Rowland, N., 551
Rubino, R., 145
Rudolph, K., 917
Russell, R. D., 573

Salama, A. I., 675
Sanchis, R., 221
Sandman, C. A., 21
Sanger, D. J., 231, 519
Sansone, M., 137
Sáry, G., 953
Scatton, B., 645
Schaefer, G. J., 797
Schechter, M. D., 7, 927
Schlumpf, M., 439
Schmitt, P., 931, 1069
Schoemaker, H., 645
Schuster, C. R., 249, 781
Seale, T. W., 275, 373
Segal, D. S., 99
Segarnick, D. J., 71
Seiden, L. S., 781
Shannon, H. E., 317
Sheiner, J. B., 721
Shibata, S., 65
Sikorowski, P. P., 525
Simansky, K. J., 253
Simke, J. P., 639
Sistek, J., 243
Skolnick, P., 17
Sloan, J. W., 987
Smith, E. R., 55
Smith, G. P., 253
Smith, J. E., 843
Smith, N. F., 77
Smith, R. J., 583
Smith, T. M., 965
Smoothy, R., 979
Snowhill, E. W., 639
Sparber, S. B., 417
Sparks, D. L., 753
Spindler, J. E., 837
Steele, T. D., 391
Stefanick, M. L., 55
Steinberg, H., 857
Stephens, E., 1045
Stolerman, I. P., 877
Stone, E. A., 749
Stripling, J. S., 573
Sullivan, A. C., 811
Supavilai, P., 671
Sutoo, D., 627
Swerdlow, N. R., 303, 499
Sykes, E. A., 857
Sze, P. Y., 215
Szumowski, D. A., 55

Tadokoro, S., 1013
Tashkin, D. P., 289, 687
Taylor, D. A., 153
Thompson, A. C., 525
Thompson, D. M., 823, 1051
Thompson, W. A., 317
Thurber, A. B., 401
Ticku, M. K., 285
Török, A., 953
Traversa, U., 237
Tretter, J. R., 541

Ueki, S., 65
Ukponmwan, O. E., 385
Ungerstedt, U., 479
Uyeno, E. T., 401

Vaccarino, F. J., 495, 499
Vaccheri, A., 43
Valentino, M. L., 567
Vande Polder, D., 469
VanderMaelen, C. P., 687
van Ree, J. M., 199
van Wolfswinkel, L., 199
Vasquez, E. C., 1069
Verberne, A. J. M., 153
Vertua, R., 237
Vetulani, J., 137, 295
Vickers, C., 905
Vickers, G., 1029
Vogel, W. H., 147
Voigt, K. H., 367

Wager-Srdar, S. A., 345
Waller, S. B., 473
Wamsley, J. K., 973
Wessberg, P., 185
Wessinger, W. D., 607, 995
White, B. C., 515
White, N. M., 37
Winsauer, P. J., 823, 1051
Wirz-Justice, A., 917
Wise, R. A., 777, 837
Witcher, J. A., 397
Wood, D. M., 529
Woods, J. H., 731
Woods, J. S., 431

Yaden, S., 529
Yamaguchi, K., 803
Yamamura, H. I., 973
Yanai, J., 215
Yim, G. K. W., 391, 701, 709
Yoshida, S., 803
Young, G. A., 457

Zacharko, R. M., 173
Zadina, J. E., 1045
Zinser, M. C., 289
Zito, K. A., 1029
Zivkovic, B., 645